Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:CRDL NASDAQ:ESLA NASDAQ:NGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$5.53-5.6%$4.82$3.35▼$17.94$128.24M3.93501,668 shs195,966 shsCRDLCardiol Therapeutics$1.24+2.1%$1.14$0.88▼$1.71$139.45M0.74711,164 shs890,173 shsESLAEstrella Immunopharma$0.82-1.8%$1.03$0.73▼$3.15$36.15M0.8549,662 shs79,902 shsNGENNervGen Pharma$1.73+3.6%$2.23$1.59▼$6.30$139.49MN/A508,267 shs599,580 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-5.63%-7.21%+40.39%+2.98%-52.41%CRDLCardiol Therapeutics+2.07%+16.51%+16.51%-24.23%+3.78%ESLAEstrella Immunopharma-1.80%-5.79%-13.17%-54.43%-3.32%NGENNervGen Pharma+3.59%-10.36%-21.36%+172,999,900.00%+172,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$5.53-5.6%$4.82$3.35▼$17.94$128.24M3.93501,668 shs195,966 shsCRDLCardiol Therapeutics$1.24+2.1%$1.14$0.88▼$1.71$139.45M0.74711,164 shs890,173 shsESLAEstrella Immunopharma$0.82-1.8%$1.03$0.73▼$3.15$36.15M0.8549,662 shs79,902 shsNGENNervGen Pharma$1.73+3.6%$2.23$1.59▼$6.30$139.49MN/A508,267 shs599,580 shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-5.63%-7.21%+40.39%+2.98%-52.41%CRDLCardiol Therapeutics+2.07%+16.51%+16.51%-24.23%+3.78%ESLAEstrella Immunopharma-1.80%-5.79%-13.17%-54.43%-3.32%NGENNervGen Pharma+3.59%-10.36%-21.36%+172,999,900.00%+172,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 2.46Hold$16.30194.76% UpsideCRDLCardiol Therapeutics 2.33Hold$8.50588.26% UpsideESLAEstrella Immunopharma 2.00Hold$8.00869.81% UpsideNGENNervGen Pharma 2.83Moderate Buy$14.00709.25% UpsideCurrent Analyst Ratings BreakdownLatest ESLA, AARD, NGEN, and CRDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026AARDAardvark Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$6.007/14/2026CRDLCardiol Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/13/2026NGENNervGen Pharma Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.007/2/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026CRDLCardiol Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/12/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/11/2026NGENNervGen Pharma TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/28/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026AARDAardvark Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.005/15/2026AARDAardvark Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$4.90 per shareN/ACRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/AESLAEstrella ImmunopharmaN/AN/AN/AN/A($0.27) per shareN/ANGENNervGen PharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$57.59M-$3.21N/AN/AN/AN/A-61.71%-56.29%N/ACRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)ESLAEstrella Immunopharma-$13.06M-$0.34N/AN/AN/AN/AN/A-397.36%9/2/2026 (Estimated)NGENNervGen PharmaN/A-$0.09N/AN/AN/AN/AN/AN/AN/ALatest ESLA, AARD, NGEN, and CRDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026CRDLCardiol Therapeutics-$0.08N/AN/AN/AN/AN/A5/16/2026Q1 2026ESLAEstrella Immunopharma-$0.0840-$0.05+$0.0340-$0.05N/AN/A5/15/2026Q1 2026NGENNervGen Pharma-$0.07-$0.09-$0.02N/AN/AN/A5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/A5/7/2026Q1 2026AARDAardvark TherapeuticsN/A-$0.99N/A-$0.99N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/ANGENNervGen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A8.068.06CRDLCardiol TherapeuticsN/A4.394.39ESLAEstrella ImmunopharmaN/A0.240.24NGENNervGen PharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/ACRDLCardiol Therapeutics12.49%ESLAEstrella Immunopharma0.35%NGENNervGen PharmaN/AInsider OwnershipCompanyInsider OwnershipAARDAardvark Therapeutics17.80%CRDLCardiol Therapeutics5.25%ESLAEstrella Immunopharma5.80%NGENNervGen Pharma5.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.88 million17.99 millionN/ACRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableESLAEstrella ImmunopharmaN/A43.03 million40.54 millionNot OptionableNGENNervGen PharmaN/A80.63 millionN/AN/AESLA, AARD, NGEN, and CRDL HeadlinesRecent News About These CompaniesNervGen Pharma (NASDAQ:NGEN) Upgraded by Wall Street Zen to Hold RatingJuly 20 at 1:15 AM | americanbankingnews.comNervGen Pharma (NASDAQ:NGEN) Upgraded by Wall Street Zen to "Hold" RatingJuly 20 at 1:11 AM | marketbeat.comNervGen Pharma Q2 EPS Estimate Decreased by HC WainwrightJuly 18 at 1:14 AM | americanbankingnews.comHC Wainwright Lowers Earnings Estimates for NervGen PharmaJuly 16, 2026 | marketbeat.comNervGen Pharma (NGEN) Gains Ground: Biotech Stock Holds Above Key Support - Iron Condor AlertJuly 14, 2026 | donanimhaber.comDNervGen Pharma Corp. : NGENJuly 13, 2026 | 247wallst.comNervGen Pharma (NASDAQ:NGEN) Now Covered by Leerink PartnersJuly 13, 2026 | marketbeat.comNervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street ZenJuly 12, 2026 | marketbeat.comNervGen Pharma (NASDAQ:NGEN) Receives $18.00 Average Price Target from AnalystsJuly 11, 2026 | americanbankingnews.comNervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink PartnersJuly 2, 2026 | tipranks.comNervGen Pharma: I Think The Biggest Risks Are Now Behind ItJuly 2, 2026 | seekingalpha.comNervGen rises as TD Cowen issues new Buy on lead assetJune 11, 2026 | seekingalpha.comNGEN Share News TodayJune 10, 2026 | uk.investing.comNervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 ProgramJune 1, 2026 | tipranks.comNervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3May 26, 2026 | tipranks.comWhy Is NervGen Pharma Stock Gaining Tuesday?May 26, 2026 | benzinga.comNervGen Pharma Reports Positive Biomechanical Gait Analysis Results for NVG-291 Demonstrating Genuine Neural Recovery in Chronic TetraplegiaMay 26, 2026 | quiverquant.comQNervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI StudyMay 26, 2026 | globenewswire.comNervGen Pharma Rings the Nasdaq Stock Market Closing BellMay 25, 2026 | nasdaq.comNervGen Pharma (NGEN) Receives a Buy from Stifel NicolausMay 25, 2026 | theglobeandmail.comNervGen Pharma stock tumbles on dilutive share offeringMay 22, 2026 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Valuation Loses Altitude as AI Risks MountBy Jeffrey Neal Johnson | June 23, 2026Tesla's New NHTSA Probe Lands at the Worst Possible TimeBy Sam Quirke | June 24, 2026EVs Are Big Winners of the Iran War—Just Not American OnesBy Jessica Mitacek | June 24, 2026Tesla Stock Surges 15% as FSD Update Backs Its Autonomy ThesisBy Sam Quirke | July 2, 2026Tesla’s Delivery Surprise Was Big—Earnings Need to Be BiggerBy Sam Quirke | July 16, 2026ESLA, AARD, NGEN, and CRDL Company DescriptionsAardvark Therapeutics NASDAQ:AARD$5.53 -0.33 (-5.63%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$5.50 -0.03 (-0.54%) As of 08:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Cardiol Therapeutics NASDAQ:CRDL$1.24 +0.03 (+2.07%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$1.22 -0.02 (-1.21%) As of 08:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Estrella Immunopharma NASDAQ:ESLA$0.82 -0.02 (-1.80%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$0.82 0.00 (-0.47%) As of 08:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.NervGen Pharma NASDAQ:NGEN$1.73 +0.06 (+3.59%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$1.74 +0.02 (+0.87%) As of 08:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different Stories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? IBM Just Had Its Worst Day Ever—What Earnings Must Prove AI Data Centers Need Power, and These 2 Industrials Are Cashing In 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Oracle Is One Step From Junk—Can It Afford the AI Boom? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
